SARS-CoV-2 Neutralization Assay System using Pseudo-lentivirus
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infects humans' lower respiratory tracts and causes coronavirus disease-2019 (COVID-19). Neutralizing antibodies is one of the adaptive immune system responses that can reduce SARS-CoV-2 infection. This study aimed to deve...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Secretariat of The Indonesian Biomedical Journal
2023-04-01
|
| Series: | Indonesian Biomedical Journal |
| Online Access: | https://inabj.org/index.php/ibj/article/view/2212 |
| _version_ | 1797845070309752832 |
|---|---|
| author | Anastasia Armimi Afina Firdaus Syuaib Katherine Vanya Marselina Irasonia Tan Dessy Natalia David Virya Chen Chikako Ono Yoshiharu Matsuura Anita Artarini Ernawati Arifin Giri-Rachman |
| author_facet | Anastasia Armimi Afina Firdaus Syuaib Katherine Vanya Marselina Irasonia Tan Dessy Natalia David Virya Chen Chikako Ono Yoshiharu Matsuura Anita Artarini Ernawati Arifin Giri-Rachman |
| author_sort | Anastasia Armimi |
| collection | DOAJ |
| description | BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infects humans' lower respiratory tracts and causes coronavirus disease-2019 (COVID-19). Neutralizing antibodies is one of the adaptive immune system responses that can reduce SARS-CoV-2 infection. This study aimed to develop a SARS-CoV-2 neutralization assay system using pseudo-lentivirus.
METHODS: The plasmid used for pseudo-lentivirus production was characterized using restriction analysis. The gene encoding for SARS-CoV-2 spike protein was confirmed using sequencing. The transfection pseudo-lentivirus optimal condition was determined by choosing the transfection reagents and adding centrifugation step. Optimal pseudo-lentivirus infection was analysed using fluorescent assay and luciferase assay. The optimal condition of pseudo-lentivirus infection was determined by the target cell type and the number of pseudo-lentiviruses used for neutralization test. SARS-CoV-2 pseudo-lentivirus was used to detect neutralizing antibodies from serum samples.
RESULTS: The plasmid used for pseudo-lentivirus production was characterized and confirmed to have no mutations. Lipofectamine 2000 reagent generated pseudo-lentivirus with a higher ability to infect target cells, as indicated by a percentage green fluorescent protein (GFP) of 12.68%. Pseudo-lentivirus centrifuged obtained more stable results in luciferase expression. Optimal pseudo-lentivirus infection conditions were obtained using puromycin-selected HEK 293T-ACE2 cells as target cells. The number of pseudo-lentiviruses used in the neutralization assay system was multiplicity of infection (MOI) 0.075. Serum A samples with a 1:10 dilution had the highest neutralizing antibody activity.
CONCLUSION: This study shows that SARS-CoV-2 neutralization assay system using pseudo-lentivirus successfully detected neutralizing antibodies in human serum, which were indicated by a decrease in the percentage of pseudo-lentivirus infections.
KEYWORDS: COVID-19, neutralizing antibody, neutralization assay, pseudo-lentivirus, SARS-COV-2 |
| first_indexed | 2024-04-09T17:32:33Z |
| format | Article |
| id | doaj.art-7e37c7e9077b4278b0d82d6afac20b57 |
| institution | Directory Open Access Journal |
| issn | 2085-3297 2355-9179 |
| language | English |
| last_indexed | 2024-04-09T17:32:33Z |
| publishDate | 2023-04-01 |
| publisher | Secretariat of The Indonesian Biomedical Journal |
| record_format | Article |
| series | Indonesian Biomedical Journal |
| spelling | doaj.art-7e37c7e9077b4278b0d82d6afac20b572023-04-18T04:03:59ZengSecretariat of The Indonesian Biomedical JournalIndonesian Biomedical Journal2085-32972355-91792023-04-011521798610.18585/inabj.v15i2.2212511SARS-CoV-2 Neutralization Assay System using Pseudo-lentivirusAnastasia Armimi0Afina Firdaus Syuaib1Katherine Vanya2Marselina Irasonia Tan3Dessy Natalia4David Virya Chen5Chikako Ono6Yoshiharu Matsuura7Anita Artarini8Ernawati Arifin Giri-Rachman9School of Life Sciences and Technology, Institut Teknologi Bandung, Jl. Ganesa No.10, Lb. Siliwangi, Bandung 40132School of Pharmacy, Institut Teknologi Bandung, Jl. Ganesa No.10, Lb. Siliwangi, Bandung 40132School of Life Sciences and Technology, Institut Teknologi Bandung, Jl. Ganesa No.10, Lb. Siliwangi, Bandung 40132School of Life Sciences and Technology, Institut Teknologi Bandung, Jl. Ganesa No.10, Lb. Siliwangi, Bandung 40132Biochemistry Research Group, Faculty of Mathematics and Natural Science, Institut Teknologi Bandung, Jl. Ganesa No.10, Lb. Siliwangi, Bandung 40132Laboratory of Virus Control, Center for Infectious Disease Education and Research, Osaka University, 1-1 Yamadaoka, Osaka 565-0871Laboratory of Virus Control, Center for Infectious Disease Education and Research, Osaka University, 1-1 Yamadaoka, Osaka 565-0871Laboratory of Virus Control, Center for Infectious Disease Education and Research, Osaka University, 1-1 Yamadaoka, Osaka 565-0871School of Pharmacy, Institut Teknologi Bandung, Jl. Ganesa No.10, Lb. Siliwangi, Bandung 40132School of Life Sciences and Technology, Institut Teknologi Bandung, Jl. Ganesa No.10, Lb. Siliwangi, Bandung 40132BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infects humans' lower respiratory tracts and causes coronavirus disease-2019 (COVID-19). Neutralizing antibodies is one of the adaptive immune system responses that can reduce SARS-CoV-2 infection. This study aimed to develop a SARS-CoV-2 neutralization assay system using pseudo-lentivirus. METHODS: The plasmid used for pseudo-lentivirus production was characterized using restriction analysis. The gene encoding for SARS-CoV-2 spike protein was confirmed using sequencing. The transfection pseudo-lentivirus optimal condition was determined by choosing the transfection reagents and adding centrifugation step. Optimal pseudo-lentivirus infection was analysed using fluorescent assay and luciferase assay. The optimal condition of pseudo-lentivirus infection was determined by the target cell type and the number of pseudo-lentiviruses used for neutralization test. SARS-CoV-2 pseudo-lentivirus was used to detect neutralizing antibodies from serum samples. RESULTS: The plasmid used for pseudo-lentivirus production was characterized and confirmed to have no mutations. Lipofectamine 2000 reagent generated pseudo-lentivirus with a higher ability to infect target cells, as indicated by a percentage green fluorescent protein (GFP) of 12.68%. Pseudo-lentivirus centrifuged obtained more stable results in luciferase expression. Optimal pseudo-lentivirus infection conditions were obtained using puromycin-selected HEK 293T-ACE2 cells as target cells. The number of pseudo-lentiviruses used in the neutralization assay system was multiplicity of infection (MOI) 0.075. Serum A samples with a 1:10 dilution had the highest neutralizing antibody activity. CONCLUSION: This study shows that SARS-CoV-2 neutralization assay system using pseudo-lentivirus successfully detected neutralizing antibodies in human serum, which were indicated by a decrease in the percentage of pseudo-lentivirus infections. KEYWORDS: COVID-19, neutralizing antibody, neutralization assay, pseudo-lentivirus, SARS-COV-2https://inabj.org/index.php/ibj/article/view/2212 |
| spellingShingle | Anastasia Armimi Afina Firdaus Syuaib Katherine Vanya Marselina Irasonia Tan Dessy Natalia David Virya Chen Chikako Ono Yoshiharu Matsuura Anita Artarini Ernawati Arifin Giri-Rachman SARS-CoV-2 Neutralization Assay System using Pseudo-lentivirus Indonesian Biomedical Journal |
| title | SARS-CoV-2 Neutralization Assay System using Pseudo-lentivirus |
| title_full | SARS-CoV-2 Neutralization Assay System using Pseudo-lentivirus |
| title_fullStr | SARS-CoV-2 Neutralization Assay System using Pseudo-lentivirus |
| title_full_unstemmed | SARS-CoV-2 Neutralization Assay System using Pseudo-lentivirus |
| title_short | SARS-CoV-2 Neutralization Assay System using Pseudo-lentivirus |
| title_sort | sars cov 2 neutralization assay system using pseudo lentivirus |
| url | https://inabj.org/index.php/ibj/article/view/2212 |
| work_keys_str_mv | AT anastasiaarmimi sarscov2neutralizationassaysystemusingpseudolentivirus AT afinafirdaussyuaib sarscov2neutralizationassaysystemusingpseudolentivirus AT katherinevanya sarscov2neutralizationassaysystemusingpseudolentivirus AT marselinairasoniatan sarscov2neutralizationassaysystemusingpseudolentivirus AT dessynatalia sarscov2neutralizationassaysystemusingpseudolentivirus AT davidviryachen sarscov2neutralizationassaysystemusingpseudolentivirus AT chikakoono sarscov2neutralizationassaysystemusingpseudolentivirus AT yoshiharumatsuura sarscov2neutralizationassaysystemusingpseudolentivirus AT anitaartarini sarscov2neutralizationassaysystemusingpseudolentivirus AT ernawatiarifingirirachman sarscov2neutralizationassaysystemusingpseudolentivirus |